SpyGlass Pharma, Inc.
SGP Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 27, 2026
$30.90
KIRA · Stoqly’s AI analyst, in plain words
- SpyGlass Pharma, Inc. lost $39.9M in fiscal 2025.
- Free cash flow was −$33.5M in fiscal 2025, — of revenue.
- SpyGlass Pharma, Inc. returned $1.5M to shareholders in fiscal 2025. The diluted share count rose 24.0%.
Market cap
$1.0B
P/E
—
Revenue
—
Net income
−$39.9M
Free cash flow
−$33.5M
Operating margin
—
SpyGlass Pharma, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$39.9M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What SpyGlass Pharma, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 26, 2026
- Legal name
- SpyGlass Pharma, Inc.
- CIK
- 0001778922
SpyGlass Pharma, Inc. · SGP
Results and finances
The last 2 fiscal years. Amounts in USD.
| Fiscal year | FY24 | FY25 |
|---|---|---|
| Sales and profit | ||
| Net income | −$29.2M | −$39.9M |
| Diluted EPS | −$16.31 | −$17.98 |
| Cash | ||
| Cash from operations | −$22.0M | −$32.7M |
| Capital expenditure | $2.0M | $0.8M |
| Free cash flow | −$24.0M | −$33.5M |
| Share buybacks | $0.0M | $1.5M |
| Share count change | — | 24.0% |
| Debt and strength | ||
| Cash and short-term investments | $16.3M | $96.4M |
| Shareholders' equity | −$60.5M | −$98.8M |
| Current ratio | 2.2x | 12.7x |
| Returns and quality | ||
| Altman Z'' | −19.8 | −9.9 |
Insiders bought, 12 months
$101M
7 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
SpyGlass Pharma, Inc. · SGP
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $30.90 a share, the company is worth $1.0B.
Source: SEC EDGAR XBRL filings (CIK 0001778922). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.